Adv Ther. 2023 doi 10.1007/s12325-023-02619-6 Epub ahead of print
This study by Bergman, et al. showed that RA patients are significantly more likely to adhere to upadacitinib within the first 12 months of prescription versus adalimumab, baricitinib, and tofacitinib. There was also a significantly lower risk of discontinuation for upadacitinib versus the other treatment prescriptions.
This retrospective analysis of Merative™ MarketScan® research databases identified RA patients who had been prescribed with one of the study drugs and had 12 months of continuous insurance enrolment pre- and post-index.